KZA 0.00% 8.0¢ kazia therapeutics limited

Ann: Cantrixil last patient visit, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,795 Posts.
    lightbulb Created with Sketch. 1723
    Preliminary analysis shows one complete response (CR) and two partial responses

    Median progression-free survival (PFS) for Part A was 5.5 months (n=9), versus thehistorical control of 3.4 months,

    Growing body of data provides strong evidence that Cantrixil is clinically active in thisvery late-stage patient population


    Safety profile consistent with prior experience: most common adverse events weregastrointestinal in nature and low-grade

    Australian lead investigator, Associate Professor Jermaine Coward, commented

    “despite recent progress in ovarian cancer, there remains an urgent need for new therapies.

    The Cantrixil phase I study was conducted in a very late-stage patient population, with few effective treatment options.

    In that context, my colleagues and I consider these data to be extremely promising.”


    Cantrixil has been able to shrink tumours and delay disease progression, demonstrating a clinically meaningful benefit
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.